CTChristopher J. D. Threapleton

Christopher J. D. Threapleton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher J. D. Threapleton has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stratifying patients for polypharmacy interventions: The case for a new biomarker?

    by Christopher J. D. Threapleton, Tess Harris, Emma H. Baker


  • Open Access

    Stratifying patients for polypharmacy interventions: the case for a new biomarker?

    by Christopher Threapleton, Tess Harris, Emma Baker

    A document by Christopher Threapleton, written on Authorea.

  • Development of a structured clinical pharmacology review for specialist support for management of complex polypharmacy in primary care

    by Christopher J.D. Threapleton, James E. Kimpton, Iain M. Carey, Stephen DeWilde, Derek G. Cook, Tess Harris, Emma H. Baker

    Aims: Polypharmacy is widespread and associated with medication‐related harms, including adverse drug reactions, medication errors and poor treatment adherence. General practitioners and pharmacists cite limited time and training to perform effective medication reviews for patients with complex polypharmacy, yet no specialist referral mechanism exists. To develop a structured framework for specialist review of primary care patients with complex polypharmacy.Methods: We developed the clinical pharmacology structured review (CPSR) and stopping by indication tool (SBIT). We tested these in an age‐sex stratified sample of 100 people with polypharmacy aged 65–84 years from the Clinical Practice Research Datalink, an anonymised primary care database. Simulated medication reviews based on electronic records using the CPSR and SBIT were performed. We recommended medication changes or review to optimise treatment benefits, reduce risk of harm or reduce treatment burden.Results: Recommendations were made for all patients, for almost half (4.8 ± 2.4) of existing medicines (9.8 ± 3.1), most commonly stopping a drug (1.7 ± 1.3/patient) or reviewing with the patient (1.4 ± 1.2/patient). At least 1 new medicine (0.7 ± 0.9) was recommended for 51% patients. Recommendations predominantly aimed to reduce harm (44%). There was no relationship between number of recommendations made and time since last primary care medication review. We identified a core set of clinical information and investigations (polypharmacy workup) that could inform a standard screen prior to specialist review.Conclusion: The CPSR, SBIT and polypharmacy workup could form the basis of a specialist review for patients with complex polypharmacy. Further research is needed to test this approach in patients in general practice.


  • Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre‐emptive pharmacogenomic testing

    by James E. Kimpton, Iain M. Carey, Christopher J.D. Threapleton, Alexandra Robinson, Tess Harris, Derek G. Cook, Stephen DeWilde, Emma H. Baker

    Aims: To investigate the longitudinal exposure of English primary care patients to pharmacogenomic drugs to inform design of pre‐emptive testing.Methods: Sixty‐three drugs were identified with dosing guidelines based on variants of 19 pharmacogenes in the Pharmacogenomics Knowledgebase on 01 September 2018. Prescribing of these pharmacogenomic drugs between 1993 and 2017 was summarised for a sample of 648 141 English patients aged 50–99 years on 01 January 2013, registered with Clinical Practice Research Datalink practices during 2011–12. Exposure of patients to pharmacogenomic drugs retrospectively (2, 10, 20 y) and prospectively (5 y) was described.Results: During 2011–12, 58% of patients were prescribed at least 1 pharmacogenomic drug, increasing to 80% over the previous 20 years. Multiple exposure was common, with 47% patients prescribed ≥2 pharmacogenomic drugs and 7% prescribed ≥5 pharmacogenomic drugs over the next 5 years. The likelihood of exposure to pharmacogenomic drugs increased with age, with 89% patients ≥70 years prescribed at least 1 pharmacogenomic drug over the previous 20 years. Even among those aged 50–59 years, 71% were prescribed at least 1 pharmacogenomic drug over the previous 20 years. The pharmacogenomic drugs prescribed to the most patients were for pain relief, gastroprotection, psychiatric and cardiovascular conditions. Three pharmacogenes (CYP2D6, CYP2C19 and SLCO1B1) accounted for >95% pharmacogenomic drugs prescribed.Conclusions: In primary care patients, exposure to pharmacogenomic drugs is extremely common, multiplicitous and has commenced by relatively early adulthood. A small number of pharmacogenes account for the majority of drugs prescribed. These findings could inform design of pre‐emptive pharmacogenomic testing for implementation in primary care.


  • Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease

    by Christopher Jd Threapleton, Sadia Janjua, Rebecca Fortescue, Emma H Baker

    Background Chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema) is a chronic respiratory condition characterised by shortness of breath, cough and recurrent exacerbations. Long‐term antibiotic use may reduce both bacterial load and inflammation in the airways. Studies have shown a reduction of exacerbations with antibiotics in comparison to placebo in people with COPD, but there are concerns about antibiotic resistance and safety. Objectives To compare the safety and efficacy of different classes of antibiotics (continuous, intermittent or pulsed) for prophylaxis of exacerbations in patients with COPD. Search methods We searched the Cochrane Airways Group Trials Register and bibliographies of relevant studies. The latest literature search was conducted on 6 February 2019. Selection criteria Randomised controlled trials (RCTs) were selected that compared one prophylactic antibiotic with another in patients with COPD. Data collection and analysis We used the standard Cochrane methods. Two independent review authors selected trials for inclusion, extracted data and assessed risk of bias. Discrepancies were resolved by involving a third review author. Main results We included two RCTs, both published in 2015 involving a total of 391 participants with treatment duration of 12 to 13 weeks. One RCT compared a quinolone (moxifloxacin pulsed, for 5 days every 4 weeks), with a tetracycline (doxycycline continuous) or a macrolide (azithromycin intermittent). The second RCT compared a tetracycline (doxycycline continuous) plus a macrolide (roxithromycin continuous), with roxithromycin (continuous) alone. The trials recruited participants with a mean age of 68 years, with moderate‐severity COPD. Both trials included participants who had between two and five exacerbations in the previous one to two years. In one trial, 17% of patients had previously been using inhaled corticosteroids. In the other study, all patients were positive for Chlamydophila pneumoniae (C pneumoniae). Overall, we judged the evidence presented to be of very low‐certainty, mainly due to imprecision, but we also had concerns about indirectness and methodological quality of the included studies. The primary outcome measures for this review included exacerbations, quality of life, drug resistance and serious adverse events. Macrolide + tetracycline versus macrolide There was no clear difference between treatments in improvement in quality of life as assessed by the Chronic Respiratory Questionnaire (CRQ). The CRQ scale ranges from 0 to 10 and higher scores on the scale indicate better quality of life. CRQ sub‐scales for dyspnoea (mean difference (MD) 0.58, 95% confidence interval (CI) ‐0.84 to 2.00; 187 participants; very low‐certainty evidence), fatigue (MD 0.02, 95% CI ‐1.08 to 1.12; 187 participants; very low‐certainty evidence), emotional function (MD ‐0.37, 95% CI ‐1.74 to 1.00; 187 participants; very low‐certainty evidence), or mastery (MD ‐0.79, 95% CI ‐1.86 to 0.28; 187 participants; very low‐certainty evidence) at 12 weeks. For serious adverse events, it was uncertain if there was a difference between combined roxithromycin and doxycycline versus roxithromycin alone at 48 weeks follow‐up after active treatment of 12 weeks (odds ratio (OR) 1.00, 95% CI 0.52 to 1.93; 198 participants; very low‐certainty evidence). There were five deaths reported in the combined treatment arm, versus three in the single treatment arm at 48 weeks follow‐up after active treatment of 12 weeks (OR 1.63, 95% CI 0.38 to 7.02; 198 participants; very low‐certainty evidence). Quinolone versus tetracycline There was no clear difference between moxifloxacin and doxycycline for the number of participants experiencing one or more exacerbations (OR 0.44, 95% CI 0.14 to 1.38; 50 participants, very low‐certainty evidence) at 13 weeks. There were no serious adverse events or deaths reported in either treatment groups. We did not identify any evidence for our other primary outcomes. Quinolone versus macrolide There was no clear difference between moxifloxacin and azithromycin for the number of participants experiencing one or more exacerbations (OR 1.00, 95% CI 0.32 to 3.10; 50 participants; very low‐certainty evidence) at 13 weeks. There were no serious adverse events or deaths reported in either treatment groups. We did not identify any evidence for our other primary outcomes. Marcolide versus tetracycline There was no clear difference between azithromycin and doxycycline for the number of participants experiencing one or more exacerbations (OR 0.44, 95% CI 0.14 to 1.38; 50 participants; very low‐certainty evidence) at 13 weeks. There were no serious adverse events or deaths reported in either treatment groups. We did not identify any evidence for our other primary outcomes. We did not find head‐to‐head evidence for impact of antibiotics on drug resistance. Authors' conclusions It is not clear from the evidence included in this review whether there is a difference in efficacy or safety between different classes or regimens of prophylactic antibiotic, given for 12 to 13 weeks to people with COPD. Whilst no head‐to‐head comparisons of antibiotic resistance were identified, concerns about this continue. The sample size in this review is small and both included studies are of short duration. Thus, there is considerable uncertainty in effects observed and the effects of different prophylactic antibiotics requires further research.


  • Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis

    by Sadia Janjua, Sofia Dias, Christopher Jd Threapleton, Alexander G Mathioudakis, Rebecca Normansell

    This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of different prophylactic antibiotics on exacerbations, quality of life and serious adverse events in people with COPD.


  • Telehealthcare for remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD)

    by Sadia Janjua, Christopher Jd Threapleton, Samantha Prigmore, Rebecca T Disler

    This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effectiveness of remote telehealthcare for monitoring and consultation with a healthcare professional for people with COPD.


  • Open Access

    Head‐to‐head oral prophylactic antibiotics therapy for chronic obstructive pulmonary disease

    by Christopher Jd Threapleton, Rebecca Normansell, Emma H Baker

    This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:


  • Palliative care in people with idiopathic Parkinson's disease who die in hospital

    by Richard W Walker, Deepta Churm, Felicity Dewhurst, Maria Samuel, Amy Ramsell, Claire Lawrie, Jessica Hill, Christopher J D Threapleton, Brian Wood, William K Gray

    Background The UK National Institute for Health and Clinical Excellence guidelines state that palliative care options for people with Parkinson's disease (PD) should be discussed. Aims To investigate whether palliative care guidelines are adhered to for people with PD who die in hospital. Setting/participants The medical notes of all people with a diagnosis of idiopathic PD who were living in two adjacent areas of northeast England and who died over a 3-year period were examined. Demographic data and specific information regarding events around the time of death were recorded. Results For the 236 patients identified, the average age at death was 82.8 years. Of these patients, 110 (46.6%) died in hospital, 56 (23.7%) at home, 59 (25.0%) in a care home and for 11 patients (4.7%) the place of death was not recorded. For those who died in hospital, only three patients, and seven relatives of patients, had had a recorded discussion with a clinician regarding their preferred place of death and only 15 (13.6%) were referred to a specialist palliative care team. Forty-six patients (41.8%) were placed on the Liverpool Care Pathway. Conclusions For those dying in hospital, there are few previously documented end-of-life care discussions with patients or their relatives. The use of end-of-life pathways and access to specialist palliative care is variable. Following the Neuberger report, the Liverpool Care Pathway is to be replaced with individual end-of-life care plans. It is important to engage patients, and their relatives, in decision making regarding preferences at the end of life.


  • Effects of intrinsic and extrinsic motivation on attention and memory

    by Lucy J. Robinson, Lucy H. Stevens, Christopher J.D. Threapleton, Jurgita Vainiute, R. Hamish McAllister-Williams, Peter Gallagher